Berlin Heals Holding AG Secures Over 7 Million CHF for Heart Failure Therapy Trials
Berlin Heals Holding AG, a pioneering MedTech startup headquartered in Switzerland, has made headlines by securing over 7 million CHF in funding to advance its innovative heart failure treatment, known as C-MIC (Cardiac Microcurrent). The company, which has been operational since 2014, specializes in developing cutting-edge medical devices designed to enhance patient outcomes in cardiac health.
C-MIC functions by delivering a consistent microcurrent that aims to improve the electrical activity of cardiac tissues, thus promoting recovery in heart failure patients. The device has already undergone initial testing in a pilot study, demonstrating promising results, leading to its recent progression into a larger International Multi-Center Controlled Randomized Clinical Trial aimed at securing CE certification.
Following this successful pilot phase, Berlin Heals is gearing up for First-In-Human studies to evaluate the safety and efficacy of alternative, less invasive implantation techniques. This funding boost comes at a critical time, allowing the company to finalize preparations for pivotal trials necessary for global regulatory approvals and reimbursement pathways.
Prior to this funding, Berlin Heals presented long-term results from its initial studies at the Technology and Heart Failure Therapeutics (THT) conference in Boston. These results have generated significant interest within the medical community, as they highlight the device's potential to enhance the quality of life for patients suffering from dilated cardiomyopathy, a form of heart failure.
John Brumfield, the CEO of Berlin Heals Holding AG, expressed his gratitude towards both existing and new investors during this fundraising round, emphasizing the significant potential that this innovative therapy holds. He remarked, "The results from our early clinical work showed strong potential for this new therapeutic approach. This funding round will give us the opportunity to test the method through several new less invasive approaches to determine which technique should be used in our Pivotal Trial for FDA and global market entry."
Echoing the enthusiasm of Brumfield, Dr. Felix Baader, Chairman of the Board, highlighted the tangible positive impacts that their innovations have had on patients' lives. Reflecting on his interactions with the patients, he noted how the advancements in their therapy have significantly restored their quality of life, enabling them to engage in activities they once enjoyed. He added, "With this funding round, we further our progress to impact many more lives ahead."
As the healthcare landscape shifts towards less invasive solutions, developments like those from Berlin Heals become increasingly relevant. The ability to offer effective alternatives to traditional heart failure treatments highlights not only a trend towards patient-centered care but also the importance of innovation in medical technology.
Berlin Heals Holding AG aims to use the newly acquired funds not only to support the ongoing clinical trials but also to continue enhancing their product development trajectory. This aligns with their overarching mission to transform heart failure care and improve patients' lives on a larger scale. The upcoming months will be crucial for the company, as they prepare to disclose findings from their ongoing clinical trials, which are anticipated to provide significant insights into the safety and efficacy of their treatment methods.
The milestone achieved by Berlin Heals Holding AG is indicative of rapid advancements within the MedTech sector, particularly in addressing complex health challenges like heart failure. As they continue to forge ahead, their commitment to innovation and patient care remains at the forefront of their endeavors.
C-MIC functions by delivering a consistent microcurrent that aims to improve the electrical activity of cardiac tissues, thus promoting recovery in heart failure patients. The device has already undergone initial testing in a pilot study, demonstrating promising results, leading to its recent progression into a larger International Multi-Center Controlled Randomized Clinical Trial aimed at securing CE certification.
Following this successful pilot phase, Berlin Heals is gearing up for First-In-Human studies to evaluate the safety and efficacy of alternative, less invasive implantation techniques. This funding boost comes at a critical time, allowing the company to finalize preparations for pivotal trials necessary for global regulatory approvals and reimbursement pathways.
Prior to this funding, Berlin Heals presented long-term results from its initial studies at the Technology and Heart Failure Therapeutics (THT) conference in Boston. These results have generated significant interest within the medical community, as they highlight the device's potential to enhance the quality of life for patients suffering from dilated cardiomyopathy, a form of heart failure.
John Brumfield, the CEO of Berlin Heals Holding AG, expressed his gratitude towards both existing and new investors during this fundraising round, emphasizing the significant potential that this innovative therapy holds. He remarked, "The results from our early clinical work showed strong potential for this new therapeutic approach. This funding round will give us the opportunity to test the method through several new less invasive approaches to determine which technique should be used in our Pivotal Trial for FDA and global market entry."
Echoing the enthusiasm of Brumfield, Dr. Felix Baader, Chairman of the Board, highlighted the tangible positive impacts that their innovations have had on patients' lives. Reflecting on his interactions with the patients, he noted how the advancements in their therapy have significantly restored their quality of life, enabling them to engage in activities they once enjoyed. He added, "With this funding round, we further our progress to impact many more lives ahead."
As the healthcare landscape shifts towards less invasive solutions, developments like those from Berlin Heals become increasingly relevant. The ability to offer effective alternatives to traditional heart failure treatments highlights not only a trend towards patient-centered care but also the importance of innovation in medical technology.
Berlin Heals Holding AG aims to use the newly acquired funds not only to support the ongoing clinical trials but also to continue enhancing their product development trajectory. This aligns with their overarching mission to transform heart failure care and improve patients' lives on a larger scale. The upcoming months will be crucial for the company, as they prepare to disclose findings from their ongoing clinical trials, which are anticipated to provide significant insights into the safety and efficacy of their treatment methods.
The milestone achieved by Berlin Heals Holding AG is indicative of rapid advancements within the MedTech sector, particularly in addressing complex health challenges like heart failure. As they continue to forge ahead, their commitment to innovation and patient care remains at the forefront of their endeavors.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.